THE RENOPROTECTIVE EFFECT OF SODIUM-GLUCOSE COTRANSPORTER2 (SGLT2) INHIBITOR DAPAGLIFLOZIN IN TYPE 1 DIABETES

被引：0
|
作者：
Hodrea, Judit [1 ]
Lenart, Lilla [1 ]
Koszegi, Sandor [1 ]
Gellai, Renata [1 ]
Balogh, Dora B. [1 ]
Vannay, Adam [2 ]
Wagner, Laszlo J. [3 ]
Szabo, Attila J. [4 ]
Fekete, Andrea [1 ]
机构：
[1] Mta Se LendUlet Diabet Res Grp, Budapest, Hungary
[2] Mta Se Pediat & Nephrol Res Grp, Budapest, Hungary
[3] Semmelweis Univ, Dept Transplanat & Surg, H-1085 Budapest, Hungary
[4] Semmelweis Univ, Dept Pediat 1, H-1085 Budapest, Hungary
来源：
PEDIATRIC NEPHROLOGY | 2015年 / 30卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
P - 216
引用
收藏
页码：1633 / 1634
页数：2
相关论文
共 50 条
  • [31] Changes in Cardiovascular Biomarkers Associated With the Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes
    Lawler, Patrick R.
    Liu, Hongyan
    Frankfurter, Claudia
    Lovblom, Leif Erik
    Lytvyn, Yuliya
    Burger, Dylan
    Burns, Kevin D.
    Brinc, Davor
    Cherney, David Z. I.
    DIABETES CARE, 2021, 44 (03) : E45 - E47
  • [32] Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
    Abdul-Ghani, Muhammad A.
    Norton, Luke
    DeFronzo, Ralph A.
    ENDOCRINE REVIEWS, 2011, 32 (04) : 515 - 531
  • [33] The Effect of SGLT2 Inhibitor Dapagliflozin on BMI in Female Adolescents with Type 1 Diabetes
    Roman, R.
    Valdivia, N.
    Ruiz, S.
    HORMONE RESEARCH IN PAEDIATRICS, 2015, 84 : 13 - 13
  • [34] Prevention of cardiovascular disease and renal failure in type 2 diabetes: sodium-glucose cotransporter-2 (SGLT2) inhibitors
    O'Sullivan, Jack W.
    BMJ EVIDENCE-BASED MEDICINE, 2020, 25 (02) : 79 - 80
  • [35] SODIUM-GLUCOSE COTRANSPORTER2 INHIBITORS IN HEART FAILURE
    Kazmierski, Wojciech
    Jurek, Jakub
    Lis, Paulina
    Lis, Anna
    Ziobro, Anna
    Ziomek, Mateusz
    Camlet, Katarzyna
    Kocur, Kinga
    PROSPECTS IN PHARMACEUTICAL SCIENCES, 2024, 22 (03): : 225 - 232
  • [36] Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats
    Hoenig, M.
    Clark, M.
    Schaeffer, D. J.
    Reiche, D.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2018, 41 (02) : 266 - 273
  • [37] Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis
    El Masri, Dana
    Ghosh, Samiran
    Jaber, Linda A.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 137 : 83 - 92
  • [38] Empagliflozin: A sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes
    Dixit, Divisha
    Yoon, Youngmin
    Volino, Lucio R.
    Mansukhani, Rupal Patel
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (22) : 1943 - 1954
  • [39] Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes
    Hedrington, Maka S.
    Davis, Stephen N.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (04) : 613 - 623
  • [40] Dapagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, Has a Low Propensity To Cause Hypoglycemia in Patients with Type 2 Diabetes
    Rohwedder, Katja
    Hruba, Veronika
    Salsali, Afshin
    Ying, Lisa H.
    Sugg, Jennifer
    List, James F.
    Parikh, Shamik J.
    DIABETES, 2011, 60 : A286 - A286
12345